• Venus Williams has demonstrated that a plant-based lifestyle can bring health benefits even for those with a physically demanding lifestyle, such as high-performance athletes
• PlantX and Williams teamed up to help company’s community adopt and maintain a plant-based lifestyle
• PlantX committed to becoming a plant-based market leader; demonstrates the ability to engage influential public figures and create a community around wholesome, healthy living

Collaboration between PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) and Venus Williams is one of the powerful alignment of core values. As someone who has overcome considerable health barriers in her sports journey with the help of a vegan diet, she is a natural fit for PlantX as a company dedicated to making plant-based living accessible to consumers. Today, Venus Williams is one of the most accomplished tennis players in the history of the sport. But ten years ago, this remarkable athlete was diagnosed with Sjögren’s syndrome, an autoimmune disease causing joint pain and fatigue that forced her to pause playing tennis. To ease debilitating symptoms and take back control of her health, she overhauled her nutrition embracing plant-based nutrition. It turned out that the decision to fuel her body with a plant-based diet was right. After only ten months, she recovered and won her 5th Wimbledon Championship and an Olympic Gold medal. (https://ibn.fm/qPw5L). Being a company committed to providing holistic access to plant-based living for consumers in North America, PlantX teamed up with this world-renowned athlete to help consumers embark on a plant-based journey which can sometimes feel overwhelming. As a result of this collaboration, a new PlantX online hub was born to showcase the company’s plant-based products carefully selected and curated by the world-famous tennis champion and entrepreneur. Williams has also become a PlantX Ambassador leveraging the company’s platform to advocate for the benefits of living a plant-based lifestyle and increase awareness of PlantX’s product offerings by promoting it to her audiences and a considerable following across her personal platforms (https://ibn.fm/2N8Tv). The dedicated section on the PlantX website, named “Venus’ Favorites,” serves as a hub where this tennis superstar shares her plant-based ideas and tips and enhances awareness and education about wholesome, healthy living that can improve sports performance (https://ibn.fm/5X1j7). The section features categories such as Venus’ Top 10 Pantry Picks, Venus’ Favorite Supplements, Venus’ Favorite Plant-Based Products and Venus’ Favorite Products For Recovery. Pantry Picks category involves products such as Alter Eco, Red Heirloom Quinoa, Westbrae Black Lentils or Earth Balance Coconut and Peanut Spread. The supplements category includes brands such as Plant Fusion, Organic India, Goli Nutrition, Sun Potion and Goldthread, offering consumers a broad range of premium products intended for optimal performance and overall wellness. Venus’ Favorite Plant-Based Products curate the list of her favorite items both for consumers and their pets. It includes brands such as Sunfood Superfood, Smart Sweets, Lenny and Larry’s Protein Cookie, Endangered Species, Pacific Food, Rao and V Dog. The recovery range includes premium products from Recover 180, Traditional Medicinals, Zola Coconut Water and Mud/Wtr. Since she overhauled her nutrition a decade ago, Williams has become a vegan icon advocating the health benefits of a plant-based lifestyle in sports performance and beyond. With her considerable experience in transitioning to a plant-based diet, she is well-placed to encourage people to learn more about this lifestyle and educate them on how to integrate this healthy lifestyle into their own lives. This makes the world-famous tennis superstar a natural fit for PlantX as a company committed to empowering consumers to make a positive lifestyle change to help them live healthier and happier lives. With this move, the company has demonstrated again the ability to engage inspiring influential figures and create an ecosystem around wholesome, healthy living. For more information, visit the company’s website at www.Investor.PlantX.com, and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Decision represents opportunity to help millions suffering from social, generalized anxiety disorders
• Global markets will reach an estimated $4 billion this year, with significant growth projected looking forward
• WHO estimates that 1 in 13 adults globally suffer from anxiety; treatment options have slow onset, undesirable side effects

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has identified social anxiety disorder, or SAD, and generalized anxiety disorder, or GAD, as the initial target indications for its proprietary psychedelic molecule CYB004 (https://ibn.fm/BQdjY). Collectively, the two global markets will reach an estimated $4 billion this year, with significant growth projected looking forward. “The decision to pursue anxiety-disorder indications for CYB004 follows months of thoughtful, in-depth work by the Cybin development team,” said Cybin CEO Doug Drysdale. “Careful consideration of many factors drives these decisions, including the prevalence of anxiety disorders, the measurable clinical endpoints, a realistic preclinical and clinical plan, along with an understanding of the effects of the molecule itself. For the Cybin team, this decision represents a further opportunity to help millions of sufferers of these all-too-prevalent disorders.” SAD, sometimes called social phobia, is categorized as the persistent and irrational fear of embarrassment and humiliation in social situations, and it is estimated to impact 3% to 7% of adults in the United States. The disorder often begins in childhood or adolescence and can contribute to major depression, substance abuse and other mental health problems. The disorder can be associated with extensive functional impairment and reduced quality of life. An estimated 3% to 6% of the U.S. adult population suffers with GAD, experiencing excessive anxiety and worry (apprehensive expectation) about a range of everyday topics/events. The disorder is one of the most common mental disorders identified in both community and clinical settings and is associated with increased use of health care services. “Based on estimates derived from currently available FDA-approved treatments, the current U.S. market is estimated at $165M with global estimates at $1.15B as of 2021,” the company announced. “The market is currently made up of multiple approved drugs still under patent protection, generics and off label use drugs. For the gad market, “current global estimates are approximately $2.99 billion and projected to grow to $4.5B by 2027,” the announcement continued. “The market is currently made up of multiple approved drugs still under patent protection, generics and off label use drugs, including benzodiazepines that carry a risk of addiction, misuse and dependence. The World Health Organization (“WHO”) estimates that 1 in 13 adults globally suffers from anxiety; however, current FDA-approved medications for anxiety disorders have slow onset of action with side effects that include weight gain, nausea, vomiting and sexual dysfunction. What’s more, many patients see no benefit from the treatments. However, studies evaluating the treatment of anxiety with psychedelics indicate a significant response to therapy, including a faster onset of action with less addictive effects. “People struggle with many different mental health challenges, but anxiety affects more people than any other,” explained Cybin chief clinical officer Dr. Alex Belser. “With the advent of the COVID-19 pandemic, rates of anxiety have increased threefold, leaving many folks in a debilitating state. We think that treatment with psychedelic medicine may help. “Our team’s previous research on anxiety at New York University and the trials conducted at UCLA and Johns Hopkins showed large magnitude decreases in anxiety after treatment with psychedelic-assisted psychotherapy,” he continued. “This is a promising approach to treat anxiety with a clear pathway.” Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Energy Fuels is making major strides toward restoring critical U.S. rare earth supply chains
• No other U.S. company is producing a product this far down the rare earth value chain
• Company working to transform into ‘America’s Critical Mineral Hub,’ with the main focus being on the White Mesa Mill

As the U.S. government appears to be throwing support and assistance behind efforts to limit its dependence on other countries for the mining and production of various metals, Energy Fuels (NYSE American: UUUU) (TSX: EFR) is increasing its efforts to produce commercial rare earth elements (“REEs”), as well as continue its commitment to uranium production, recycling and environmental and social responsibility (https://ibn.fm/XBT1k). “Without a doubt, Energy Fuels is making major strides toward restoring critical U.S. rare earth supply chains, while also maintaining our position as the leading U.S. uranium producer,” said UUUU’s president and CEO Mark S. Chalmers. “On rare earths, our efforts over the past several months culminated in the announcement on March 1 that Energy Fuels and Neo Performance Materials were creating a new, U.S.-European rare earth supply chain. “In early March, we began to receive shipments of rare-earth-rich natural monazite sands from Chemours’ Georgia heavy mineral sand operations,” he continued. “In late-March, we began to ramp-up production of an intermediate rare earth product at our White Mesa Mill in Utah using monazite from Chemours. This is expected to be a high-value product ready to be separated and refined into value-added rare earth products at Neo’s plant in Europe. At this time, no other U.S. company is producing a product this far down the rare earth value chain.” Energy Fuels first announced its intended entry into the REE sector in April 2020 (https://ibn.fm/j2viA). The company made the decision to enter the space after months of deliberate review and testing, including discussions with various technical experts and the U.S. government. The company noted at the time that the U.S. government was actively seeking a domestic source of REE minerals, which are needed for national defense. Energy Fuels identified its Utah-based White Mesa Mill as uniquely suited to potentially receive and process a certain type of ore called monazite for the recovery of REEs, along with uranium. Since that time, the company has identified and reached a series of essential landmarks on the journey to becoming a key producer of REEs. “However. . . we have much bigger rare earth plans, and the momentum is building rapidly as we execute our purposeful strategy,” said Chalmers. “We are now taking real steps toward designing and building fully integrated, U.S. rare earth production capabilities. . . . We continue to believe Energy Fuels has distinct advantages in the rare earth sector. Monazite ore has superior distributions of the high-value magnetic rare earths, including NdPr and ‘heavy’ rare earths, versus most other rare earth minerals mined around the world, and monazite is currently produced as a byproduct of existing heavy mineral sand operations. We are also taking steps to utilize licensed and existing facilities at the White Mesa Mill to process the monazite into value-added products. This is a highly capital efficient initiative. “At the same time, we are transforming our company into ‘America’s Critical Mineral Hub,’ with the main focus being on the White Mesa Mill in Utah,” conclude Chalmers. “While nearly all current and future nuclear reactors are fueled by uranium, other clean energy and advanced technologies, including electric vehicles renewable energy and batteries, require other critical minerals that Energy Fuels produces. A robust market for responsibly produced, American clean energy products and technologies, made by American workers, is possible in the U.S.” For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• WTER to join Russell Microcap Index effective June 28, 2021
• Addition to prestigious microcap Index will only heighten awareness of WTER stock on Wall Street
• Membership in Russell Microcap Index includes automatic listing in other appropriate growth and value style indexes

The country’s largest independent alkaline water company, The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), will join the Russell Microcap(R) Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021 (https://ibn.fm/yyHMg). The Russell indices are heavily used and relied on by investment managers as well as institutional investors. “We are honored to be included in the Russell Microcap Index,” said WTER president and CEO Richard A. Wright. “Joining the Nasdaq exchange two and a half years ago brought our company visibility in the investment community. Our addition to the Russell Microcap Index will only heighten the awareness of our stock on Wall Street.” Russell indexes are part of FTSE Russell, a leading index provider known for providing critical innovative benchmarking, analytics and data solutions for investors around the world. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries; its indexes cover 98% of the global investable market. WTER noted that an estimated $10.6 trillion in assets are benchmarked against Russell’s US indexes. Along with membership in the Russell Microcap Index comes automatic inclusion in other appropriate growth and value style indexes. Membership in those indexes is determined by FTSE Russell based on objective, market-capitalization rankings and style attributes. The Alkaline Water Company’s inclusion in these indexes is clear evidence of its success in building a strong, successful beverage portfolio that includes Alkaline88(R), known for its superior hydration with a perfect 8.8pH balance; A88 Infused(R), which includes flavored waters and CBD waters; and A88CBD(TM), a line of CBD ingestibles and topicals. The company is dedicated to purity, quality, value and taste, and is focused on making a difference in the water people drink. “According to Nielsen for the 52 weeks ending 4/24/21, we continued to outperform the category over 2x in sales volume and over 13x in unit volume,” said Wright. “We are now the largest independent alkaline water company in the country, and we are seeing accelerated growth in our single-serve, aluminum and flavored waters. Our clients, consumers and shareholders are all important to us, and we’re working hard to add value for each of them.” For more information, visit the company’s website at www.TheAlkalineWaterCo.com and www.a88CBD.com. NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

• More than 3,200 pharmaceutical and biotech companies, plus government and academic organizations attended latest BIO Conference
• Predictive Oncology’s Helomics, TumorGenesis, Soluble Biotech all attended the virtual conference from June 14-18, 2021
• Companies leveraged different components of the conference to entertain new partnerships or customers

Every industry has a revolving calendar of events, but some are “must attends” due to their global reach and prospective deal flow, like conferences put on by Biotechnology Innovation Organization, or just “BIO” as it’s known. This year, three wholly owned subsidiaries of Predictive Oncology (NASDAQ: POAI) – Helomics, TumorGenesis and Soluble Biotech – attended BIO DIGITAL, a premier international biotech partnering event held virtually on June 10-11 & 14-18, 2021. The Predictive Oncology companies attended the event during the second leg of the conference. BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the U.S. and in 30+ countries. This year’s virtual conference attracted more than 3,200 pharmaceutical and biotech companies, in addition to government and academic organizations. Each year, the BIO events feature presentations from key opinion leaders and some of the world’s brightest scientific minds discussing the latest breakthroughs in medicine. While informative, the thrust of attending for companies like that of Predictive Oncology is networking and one-on-one sessions that can result in new partnerships or customers. “In previous conferences Soluble Biotech has typically received more than a dozen requests for proposals, leading to new contracts for their main service of providing protein therapeutic formulations (i.e., formulations for vaccines, antibodies, virus-like particles),” said Predictive Oncology CEO J. Melville Engle. He added that the Helomics unit is leveraging BIO’s one-on-one sessions to showcase its precision medicine discovery platform branded “PeDAL” (https://ibn.fm/To6tz). PeDAL, an acronym for Patient-centric Drug Discovery using Active Learning, is a unique technology that combines a proprietary, clinically-validated tumor profiling assay, a knowledgebase of proprietary and public data together with active learning. The active learning allows for the efficient exploration of drug responses against a large diverse patient biology “space.” The conference allowed TumorGenesis to market its products and services specialized on culturing cancer cells from ovarian and breast cancers that more accurately mimic a patient’s tumors. TumorGenesis technology effectively “fools” ovarian cancer cells into growing outside the body, where they can be studied to better understand the efficacy and safety of cancer drugs specific to the patient. These improved ex-vivo tumor models can then be used by researchers to investigate cancer and by clinicians to develop patient-specific treatment plans. Engle summed up the comprehensiveness of POAI’s divisions in saying, “Our unique approach allows Pharma therapeutic groups to see how we embrace the complexity and diversity of patient tumors in a highly-scalable and efficient experimental exploration of drugs and drug combinations for patient-specific populations.” And, thanks to organizations like BIO, all the companies’ utility and value can be showcased at global scale. For more information, visit the company’s website at www.Predictive-Oncology.com. NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Emaginos has built a system that transforms schools using a model that perfectly meets the demands the pandemic exposed
• DLS offers systemic transformation to a K-12 public education system that encourages and fosters students’ desire to learn
• The company is raising capital for further development and placement of its transformational public school model

Like so many other educational entities, Emaginos Inc. has been deeply impacted by COVID-19. Unlike many other educational organizations, Emaginos — and its Discovery Learning System — is perfectly prepared for the changes that the global pandemic has forced upon a generation of K-12 students struggling to find the most effective way to learn. Emaginos is a REG-A company with news posted on Yahoo Finance in the business of transforming K-12 public education; see the website if interested in investing. “COVID-19 has created a teachable moment for Emaginos,” said Emaginos president Allan Jones in an open letter to educators (https://nnw.fm/DsAtq). (https://ibn.fm/CJP2q). “Social distancing forced K-12 education leaders to adopt new ways for teachers to teach and students to learn. Serendipitously, Emaginos has built a Discovery and Learning system (‘DLS’) that transforms schools using a model that perfectly meets the demands the pandemic exposed. COVID did not create the needs. They were already there, hidden beneath decades of traditional educational pedagogy. The Emaginos model was an idea in search of its time.” A teachable moment, explains Jones, “is that wonderful time when the student wants to learn what the teacher wants to teach.” In this instance, Emaginos is always ready to learn and grow as it leads the way forward in transforming education. The Emaginos Discovery Learning System offers a systemic transformation from the current teacher-centered model to a K-12 public education system that encourages and fosters students’ desire to learn. The company is in the process of raising capital for further development and placement of its transformational public school model. While now is a critical moment for Emaginos as it launches its exclusive DLS model into the educational space, it is also a critical moment for those looking to become involved in companies, projects and ideas with the potential to make a profound impact on the world. Emaginos is the first company with an actionable plan to transform and improve public schools rather than replace them (https://nnw.fm/1wUQM). (https://ibn.fm/yFInO). The Emaginos model utilizes existing funding, facilities and staff to improve educational approaches and outcomes, in many cases savingschool districts money as they subscribe to and implement the Emaginos platform. “Good teachers know how to recognize [teachable] moments and take advantage of them,” Jones points out in his open letter. “Great teachers know how to create them.” Emaginos is seizing an opportunity to provide the tools that empower great teachers as they strive to fill each school day with teachable moments that constantly challenge, inspire and support students. For more information about Emaginos and to learn about investment and shareholder opportunities, visit www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://nnw.fm/Emaginos https://ibn.fm/Emaginos

• GPFT customers can convert crypto of choice at checkout to make online purchases.
• Announcement demonstrates company’s outreach to growing demographic of early adopters, younger buyers.
• Grapefruit is building a well-earned reputation for pioneering future-looking ideals and products.

In an industry known for embracing the use of cryptocurrency (https://ibn.fm/14OmW), Grapefruit USA (OTCQB: GPFT) joined other leaders in the cannabis space in paving the way forward when it announced that it is accepting cryptocurrency as payment on its recently launched e-commerce store (https://ibn.fm/ymP2R). The company noted that its customers who prefer Bitcoin, Ether, Bitcoin Cash, Litecoin, Dogecoin or Monero will now be able to “convert” their crypto of choice at checkout to make online purchases. “Grapefruit’s THC-free hemp-derived CBD Hourglass technology-driven products, just like cryptocurrencies and the blockchain, are the future, and Grapefruit’s acceptance of crypto as payment demonstrates GPFT’s outreach to the explosively growing demographic of crypto early adopters and other ‘younger’ buyers who also seek the holistic benefits of Grapefruit’s THC-free, hemp-derived Hourglass time-release CBD products,” said Grapefruit CEO Bradley J. Yourist. “Everyone, young and old, experiences sore muscles from working out and other aches and pains, and our THC-free hemp-derived CBD Hourglass-powered products can provide a solution for all demographics — whether they choose to pay by American Express Platinum or Dogecoin on our accurate and secure payment platform. “We envision the days after Sen. Schumer succeeds in his efforts to decriminalize THC, and customers from the 50 states and throughout the world will be able to use crypto to pay for purchases of our full-spectrum THC Hourglass time-release technology-powered products through our e-commerce platform,” Yourist continued. As Yourist alluded, Grapefruit is building a well-earned reputation for pioneering future-looking ideals and products. The company’s flagship product features cutting-edge science and technology that solves the age-old problem of THC and other cannabinoids not being easily absorbed through the skin. Grapefruit’s Hourglass topical cream uses patented microsized particles to slowly deliver THC and a wide range of cannabinoids through skin topical administration. No other topical cream product on the market provides users with the holistic benefits of the range of cannabinoids found in Hourglass, including THC+CBD, CBN, CBG, Delta8, THCV and CBE. The development of Hourglass and the acceptance of crypto are symbolic of Grapefruit’s commitment to being a leader in the cannabis industry by using science and technology to create truly disruptive products for both the recreational and medicinal cannabis marketplaces.  The company is focused on delivering patented cannabis and hemp-derived products that fundamentally change the way consumers use THC, CBD and hemp. Grapefruit is devoted to selling only the highest-quality, plant-based, independently tested and reliable cannabis and hemp products and will make no claims unless clinically validated. All products marketed and sold on the company’s new e-commerce website will be thoroughly tested and include a QR-coded certificate of analysis, which will provide consumers with a complete list of third-party-verified ingredients certifying each product’s cannabinoid content, purity and safety. In addition, the company does not recommend investing in cryptocurrencies without doing due diligence and obtaining the advice of an investment advisor or other counsel. To find out more about the company and its game-changing Hourglass time-release cannabinoid delivery cream, please visit www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT

Virtual Event Date: June 30, 2021 1:30pm EDT Scientists, medical researchers, marketers, entrepreneurs, enthusiasts, thinkers, and developers of psychedelic products are invited to attend the Microdose Psychedelic Capital: June 2021, a virtual investment conference live streaming on Wednesday, June 30, 2021. This virtual platform showcases a wonderful opportunity for companies, businesses, and heads of commercial as well as non-profit initiatives to meet and reach out to the length and breadth of industry leaders of the psychedelic medicine arena. Eminent leaders and passionate environmentalists are invited as speakers and share their insights, keynotes and ideas on the present status, growth and development of psychedelic drugs and plant-based formulations. Companies like Gwella Mushrooms will be showcasing their portfolio, and explain the amazing life-changing benefits of mushrooms to humans and their environmental sustainability. Co-founder and CEO, Peter Reitano, has over a decade of experience in working with top cannabis companies. The company is in the process of exploring how the amalgamation of psychedelic mushrooms into wellness formulations can benefit the mind, body, and spirit. The conference will subsequently play host to a number of corporate presentations, including:

• ST Biosciences, a global phytopharmaceutical company involved in the research, development, cultivation, processing and commercialization of pharmaceutical and medicinal cannabis products.
• Return Health, whose focus is on the psychedelic medicine dementia initiative.
• Negev Capital, a Psychedelic Medical Intervention Investment Fund will host an exciting roundtable symposium that will explore the intersection between the science of psychedelic mood enhancing actions, and the strategic drug development decisions that are being made in advance of the science.

The roundtable features: Edward Sellers, MD, PhD, FRCPC, FACP, Scientific advisory chair at Diamond Therapeutics & Professor Emeritus, Pharmacology and Toxicology, Medicine and Psychiatry at the University of Toronto; Carol Routledge, Chief Scientific and Medical Officer at Small Pharma; Dr. Gideon Shapiro Ph.D, Vice President of Discovery at Bright Minds; and is moderated by Negev Capital partners Stuart Seidman and Ken Belotsky. All ticket holders to the event will get access to free recordings for life that they can check in their free time. On purchasing a ticket, all attendees will receive access to the event platform through a link received in their email. The event can be easily accessed on a mobile device. However, to avail all the features of the app, it is recommended that users run the application on their computer devices. This networking avenue holds tremendous opportunities for professionals to build relationships and get access to pre-IPO investment opportunities. They will also gain knowledge and get know-how with the latest development and innovations in the psychedelic industry. Plant-based investor from diverse backgrounds from all over the globe will attend the event, offering discussions on the latest techniques of cultivation, maintenance, and the roadblocks encountered in the sale and distribution of psychedelic medicine. To know more about the event, please visit https://ibn.fm/TsvGC. About Microdose Psychedelic Insights Microdose Psychedelic Insights aims to unlock the potential of psychedelics through Industry events, market intelligence, original, evidence-based content, strategy and community. We enable and empower society at large to make better, more mindful decisions about psychedelics and its intersection with healthcare, medicine and personal growth. We work with the industry’s most influential stakeholders, some of the world’s best-known brands and an unrivalled network of scientists, researchers, analysts, innovators, investors and advisors. About Psychedelic Capital  This online event programming is dedicated to providing investment grade information for the nascent psychedelic sector and presents a curated group of CEOs, financial experts, thought leaders and investment luminaries from around the globe. Presentations are 30 minutes in length, with 10 minutes always allocated to a one-on-one Q&A session with the audience. Psychedelic Capital features the top companies, latest IPOs, newest opportunities and deepest insights into the emerging psychedelic space.

• Knightscope designs and develops autonomous security robots (“ASRs”) that use the latest in technological advances to provide clients with a sense of security
• The company’s ASR robots’ have a wide range of capabilities that depend on analysis of video, audio, thermal and digital data cues, integrated through the remote access Knightscope Security Operations Center (“KSOC”)
• The KSOC’s functionality serves client security needs, but in an evolving budgetary landscape could find uses in monitoring and managing business intelligence, policy compliance and liability reduction efforts as well
• AI-driven analytics are expected to be a standard element in more than half of new video surveillance installations by 2023

Corporations are finding that their IT departments and security personnel are increasingly connected. The functionality and availability of artificial intelligence-enhanced technology are granting C-level executives options for managing their facilities and products that once were only imagined in the science fiction realm. A recent article appearing in the e-magazine Security notes that advanced video management systems (“VMS”) have become an ROI talking point during budget cycle reviews as security personnel explain the potential for companies to greatly enhance their ability to monitor and manage business intelligence, policy compliance and liability reduction efforts. “Today’s intelligent VMS solutions enable video to be sharable in more secure ways with business operations and crisis response teams. No longer do VMS platforms have to be designed by and exclusively used for security,” the article states (https://ibn.fm/DaHnr). “The new capabilities for cloud storage, edge analytics, AI processing, privacy protection for GDPR and integration with other data sources through robust APIs allow businesses to leverage their investment in VMS technology to directly support their bottom line.” Autonomous security robot (“ASR”) innovator Knightscope is largely focused on preventing and detecting crime using an API that is adaptable to its clients’ needs. Although the company’s autonomous robots have been hailed as the means of reducing threats and risks in crime-prone locations (https://ibn.fm/Dhv0P), their Knightscope Security Operations Center (“KSOC”) browser-based user interface provides a capability that goes beyond fulfilling simple security needs, much like the VMS systems Security mentions. The KSOC’s integrated system allows human operators to interact from a remote position with people in the environment surrounding the robot. The company’s K5 model stands at over 5 feet tall and uses 360-degree high-definition night and day video capture positioned at eye-level, live streaming and recorded high-definition video transmission in conjunction with analytic features such as automatic license plate recognition, “parking meter”-type analysis of how long vehicles are left in a parking lot, time-stamped people detection with an accompanying alert system, thermal imaging with accompanying alerts that has had the potential to detect COVID hazards during the pandemic and digital signal detection in sensitive data areas. Knightscope’s product developers are continually working to ensure their ASR models are using technological tools that are not only functional but reputable, and that operators can access real-time data at any time of day or night from a centralized control vantage point. The Security article cites Gartner publication research that forecasts AI-driven video analytics will be a standard element in more than half of new video surveillance installations by 2023 and that 70 percent of security surveillance cameras will have real-time monitoring and analytics functions embedded in them straight from the manufacturer by 2025 (https://ibn.fm/8RmaS). Knightscope’s visionary approach to corporate and government client security has kept it at the forefront of the trends, and has secured it the backing of more than 28,000 investors in capital raises since its inception in 2013 even though the company is not publicly listed at this time. For more information, visit the company’s website at www.Knightscope.com and if you have a need for subscription service you may request a private demonstration of the technology at www.Knightscope.com/demo. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• With the launch of its Big Data Insights Division (Sapientus), FingerMotion is now capable of using its access to real users’ data to create behavioral analytics and data insights that ensure it can capitalize on the emerging big data opportunities
• A recent report notes that consumer analytics is proving vital in customer-facing industries such as banking, financial services, insurance, automotive, and healthcare
• FingerMotion, which announced an agreement with Pacific Life Re-Insurance early this year, appears to be leveraging the appeal for big data insights in the insuratech business
• The company expects multiple contracts relating to its insuratech products before the end of the year

Since its founding in 2016, FingerMotion (OTCQX: FNGR) has continually evolved by establishing various divisions that have undergirded the development of the newly launched Big Data Insights division (Sapientus), making the company capable of capitalizing on the emerging big data trends in China. FNGR believes its future lies in the Sapientus division (https://ibn.fm/ZOKLu) and a look at the various big data opportunities in China suggests the reasoning behind this belief. China is the largest manufacturing country, thanks, in part, to the availability of lower-wage workers and growing technologies. However, its cost advantage is increasingly under threat from other Asian countries and needs offer higher value by using tools like big data. Also, as the government’s strategy focuses on spurring equitable, efficient, secure, and sustainable economic development as well as digital transformation, the big data market is expected to expand in the next few years. According to an International Data Corporation report, China’s big data market is expected to increase to over $20 billion by 2024, representing a 145% increase from the figure reported in 2019. In fact, between 2019 and 2020, the market size had already grown by 15.9%, eclipsing the $10 billion mark for the first time. The upward trend is attributable to fintech innovation and a government-led digital transformation. Already, banking, telecommunication companies, and local governments have invested in big data infrastructure, accounting for 38% of the total spending in 2020 (https://ibn.fm/iFKkQ). Further, a recent report by ResearchAndMarkets.com notes that investment opportunities of big data technology in China are expected to grow at a 30% CAGR between 2021 and 2026. “Big data has enormous potential to revolutionize the Chinese economy,” reads the report (https://ibn.fm/ioSnG). “China has the world’s largest consumer market. The world’s workshop, China, is producing countless goods for export. Big data can offer critical insights into China’s highly valued consumer market and assist Chinese firms trying to engage in high-value economic activities.” The report indicates that the amount of data generated from China’s massive consumer market is already huge and will only increase in the coming years. Touted as the solution to efficiently handle these large volumes of data, big data is proving fundamental for companies competing in China, especially those in the automotive and healthcare, as well as banking, financial services, and insurance (“BFSI”) sectors as they are predominantly B2C-focused entities. Thanks to a relationship forged with the three largest telecommunication companies in China, FingerMotion has access to a secure database of more than 1.5 billion users, from which it retrieves only demographic information to create data packets that personify the mobile data and subsequently generate data insights and behavioral insights (https://ibn.fm/9XKcf). Given that China’s population currently stands at 1.41 billion, according to a census conducted in late 2020 (https://ibn.fm/ttoJ2), but also bearing in mind that many telecommunication customers use multiple sim cards, FNGR appears to be ahead of the data insights curve in terms of access to real users’ data. The company is initially focusing its big data efforts on insuratech products, leveraging the ever-expanding need for data insights and consumer analytics by B2C companies in the BFSI industry. In January, FingerMotion announced an agreement with Pacific Life Re-Insurance and, while reporting the company’s financial position, CEO Martin Shen expressed optimism that by the end of calendar 2021, FNGR expects multiple contracts relating to its insuratech products. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR